PLx Pharma Inc. to Discuss 2017 Third Quarter Financial Results on November 10, 2017 Conference Call
November 02 2017 - 08:00AM
PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a
late-stage specialty pharmaceutical company focused on
commercializing two patent-protected products, Aspertec™ 325 mg and
Aspertec™ 81 mg (referred to together as “Aspertec”™), today
announced that the Company will release its 2017 third quarter
financial results on Friday, November 10, 2017, before the U.S.
financial markets open.
Natasha Giordano, President and Chief Executive Officer, and
Rita O’Connor, Chief Financial Officer, will host a conference call
to discuss the results as follows:
Date |
Friday, November 10,
2017 |
Time |
8:30 a.m. EST |
Toll free (U.S.) |
(866) 394-2901 |
International |
(616) 548-5567 |
Webcast (live and
replay) |
www.plxpharma.com under
the ‘Investor Relations’ section. |
A replay of the conference call will be available for two weeks
after the call's completion by dialing (855) 859-2056 (U.S.) or
(404) 537-3406 (International). The conference ID for the
replay is 3388277. The archived webcast will be available for 30
days via the aforementioned URL.
About AspertecAspertec 325 mg is
an FDA-approved aspirin product being developed to provide
high-risk cardiovascular and stroke patients with more reliable and
predictable antiplatelet efficacy as compared to enteric-coated
aspirin, while also reducing the adverse gastric events common in
an acute setting. PLx is focused on completing manufacturing
scale-up and label finalization for Aspertec 325 mg aspirin dosage
form and preparing an sNDA for Aspertec 81 mg maintenance dose
form.
About PLx Pharma Inc.PLx Pharma
Inc. is a late-stage specialty pharmaceutical company focused
on developing its clinically validated and patent-protected
PLxGuard™ delivery system to provide safe and effective aspirin
products. The PLxGuard delivery system works by targeting delivery
of active pharmaceutical ingredients (API) to various portions of
the gastrointestinal (GI) tract. PLx believes this has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce acute GI side
effects—including erosions, ulcers and bleeding—associated with
aspirin and ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
Contact Investor Relations:Lisa M. Wilson, In-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Feb 2024 to Mar 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Mar 2023 to Mar 2024